Predict your next investment

Venture Capital
vensanacap.com

See what CB Insights has to offer

Investments

11

Portfolio Exits

2

Funds

1

About Vensana Capital

Vensana Capital is a venture capital & growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology.

Vensana Capital Headquarter Location

2601 W 76th Street Suite 20

Minneapolis, Minnesota, 55435,

United States

612-254-1170

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vensana Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Vensana Capital in 1 Expert Collection, including Medical Devices.

M

Medical Devices

412 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

Research containing Vensana Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Vensana Capital in 1 CB Insights research brief, most recently on Jun 25, 2021.

Latest Vensana Capital News

Company Uses AI, Machine Learning to Tackle Heart Disease

Sep 8, 2021

Company Uses AI, Machine Learning to Tackle Heart Disease Company Uses AI, Machine Learning to Tackle Heart Disease Cleerly was founded in 2017 to leverage advanced imaging science to identify people at risk of heart attacks. Business Wire09.08.21 Cleerly , a company creating a new standard of care for heart disease, launched with $43 million in Series B funding and unveiled its first-of-its-kind digital care pathway solution for heart attack prevention. The financing, which was led by Vensana Capital with participation from LRVHealth, New Leaf Venture Partners, DigiTx Partners, the  American College of Cardiology , Cigna Ventures, and existing investors, brings Cleerly’s total funding to $54 million. Cleerly was founded based on more than a decade of foundational research its team used to develop the proprietary artificial intelligence (AI) and machine learning algorithms that power its revolutionary capabilities. This research was conducted in The Dalio Institute for Cardiovascular Imaging at the New York-Presbyterian Hospital and Weill Cornell Medicine and evolved into the Cleerly technologies. The research includes large-scale clinical trials with more than 50,000 patients, comprising the most extensive body of coronary imaging research to study how imaging can be used to better understand heart disease and project patient outcomes. Cleerly was founded in 2017 to translate this advanced imaging science into the company’s pioneering approach for identifying people at risk of heart attacks. “Advanced imaging has been key to diagnosing and preventing the most common causes of cancer for years, but we’re not using it yet to prevent the most common cause of death. We use 3D mammograms, colonoscopies and lung CT scans to find and prevent breast, colon and lung cancer, but we haven’t had similar capabilities for the world’s number one killer—heart disease,” said James K. Min, M.D. FACC, founder and CEO of Cleerly. “Through the application of artificial intelligence that is constantly being refined with our unprecedented volume of accruing and exclusive clinical data, Cleerly is finally bringing heart disease diagnosis and prevention into the 21st century.”   Heart attacks are a public health epidemic, accounting for one in every four deaths. However, the causes of heart attacks have been poorly understood and difficult to identify. For example, measuring cholesterol is widely relied upon as an indicator of risk, but there is more than 80 percent overlap of cholesterol levels for those who will, versus those who will not experience heart attacks. Further, the first symptom of heart disease in more than 50 percent of individuals diagnosed with coronary artery disease is a heart attack or death. A Pioneering Approach for Preventing Heart Disease Cleerly’s digital care pathway leverages non-invasive coronary computed tomography (CT) angiography to perform comprehensive coronary artery phenotyping through AI-enabled and U.S. Food and Drug Administration-cleared solutions. This technology is based on millions of annotated lab images used to build more than two dozen proprietary algorithms capable of quantifying and characterizing the presence, extent, severity and type of coronary artery disease and other cardiovascular disorders. Through this new visibility and understanding of coronary artery disease, Cleerly is transforming the field of cardiovascular medicine by introducing a multidimensional approach to serve each and every stakeholder in the care pathway—from imaging physicians, to clinicians, to patients, to payers. “We see Cleerly as the future of how coronary artery disease will be evaluated, and we support the company’s mission to tailor a personalized approach to diagnosis, management and treatment, and to validate all of this with world-class clinical evidence of utility and cost-effectiveness” said Justin Klein, M.D., JD, managing partner at Vensana Capital. “With Cleerly’s industry-leading technology platform and inherent value propositions, we believe Cleerly is ideally positioned to inform a new standard of care for how we manage coronary artery disease at scale.”   For example, beyond end-to-end AI for deep coronary phenotyping, Cleerly’s solutions include tools for clinicians—such as primary care physicians or general cardiologists—to understand the importance of the data without having to understand advanced imaging. It also includes interactive and personalized, patient-facing tools to help improve health literacy and empower patients with knowledge. Finally, quantitative tools enable patients and their care team to track coronary artery disease changes over time. With its Series B funding, Cleerly will scale its commercial reach, expand operational capabilities and strategic partnerships, and continue to grow its focus on industry-leading research and development. As part of the financing, Klein of Vensana Capital, Tripp Peake of LRVHealth, and Vijay Lathi of New Leaf Venture Partners will join Cleerly’s Board of Directors. “We are proud to be the partner of choice for companies like Cleerly who share our commitment in breaking boundaries and accelerating innovation to unlock bold, new opportunities that create better health for the people we serve,” said Tom Richards, global lead, strategy and business development at Cigna. “With these digital health partnerships and through our end-to-end care approach, we see significant opportunity to accelerate innovation in cardiovascular disease while improving patient experience, reducing costs and improving outcomes.”   Through value-based precision diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Headquartered in New York City, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. PR Newswire 09.07.21 PR Newswire 09.02.21 Tissium 09.01.21 Stereotaxis Inc. 09.01.21 Business Wire 08.27.21 Globe Newswire 08.26.21 PR Newswire 08.26.21 Texas A&M Engineering 08.19.21 Business Wire 08.19.21 PR Newswire 08.16.21 Heart Rhythm Society 08.13.21 Acutus Medical 08.12.21 U.S. Food and Drug Administration 08.12.21 Philip Morris International Inc. 08.11.21 Heart Rhythm Society 08.06.21

Vensana Capital Investments

11 Investments

Vensana Capital has made 11 investments. Their latest investment was in Cleerly Coronary as part of their Series B on June 6, 2021.

CBI Logo

Vensana Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/21/2021

Series B

Cleerly Coronary

$43M

Yes

4

5/27/2021

Unattributed VC - II

GPB Scientific

$18M

No

2

2/10/2021

Series C

Personal Genome Diagnostics

$103M

Yes

4

1/5/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

10/29/2020

Series G

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/21/2021

5/27/2021

2/10/2021

1/5/2021

10/29/2020

Round

Series B

Unattributed VC - II

Series C

Series B

Series G

Company

Cleerly Coronary

GPB Scientific

Personal Genome Diagnostics

Subscribe to see more

Subscribe to see more

Amount

$43M

$18M

$103M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

2

4

10

10

Vensana Capital Portfolio Exits

2 Portfolio Exits

Vensana Capital has 2 portfolio exits. Their latest portfolio exit was CVRx on June 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/30/2021

IPO

$991

6

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

6/30/2021

00/00/0000

Exit

IPO

Subscribe to see more

Companies

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Sources

6

10

Vensana Capital Fund History

1 Fund History

Vensana Capital has 1 fund, including Vensana Capital I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/4/2019

Vensana Capital I

Diversified Private Equity

$225M

1

Closing Date

9/4/2019

Fund

Vensana Capital I

Fund Type

Diversified Private Equity

Status

Amount

$225M

Sources

1

Vensana Capital Team

2 Team Members

Vensana Capital has 2 team members, including current Founder, Managing Partner, Kirk G. Nielsen.

Name

Work History

Title

Status

Kirk G. Nielsen

Founder, Managing Partner

Current

Justin Peter Klein

Managing Partner

Current

Name

Kirk G. Nielsen

Justin Peter Klein

Work History

Title

Founder, Managing Partner

Managing Partner

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.